
TMP269

产品编号: D50789

CAS: 1314890-29-3

分子式: C₂₅H₂₁F₃N₄O₃S

纯度: ≥98%

InChi: InChI=1S/C₂₅H₂₁F₃N₄O₃S/c26-25(27,28)22-31-20(32-35-22)17-7-4-8-18(13-17)21(33)29-15-24(9-11-34-12-10-24)23-30-19(14-36-23)16-5-2-1-3-6-16/h1-8,13-14H,9-12,15H2,(H,29,33)

InChi Key: HORXBWNTEDOVKN-UHFFFAOYSA-N

Smiles: O=C(NCC1(CCOCC1)C1=NC(=CS1)C1C=CC=CC=1)C1C=CC=C(C=1)C1N=C(ON=1)C(F)(F)F

外观: 固体粉末

作用通路: HDAC

溶解性: DMSO up to 50 mM

保存条件: Store in dry, dark place for one year.

产品介绍: TMP269 is a highly potent, selective and cell-permeable class IIa HDAC inhibitor with IC₅₀ of 126 nM, 80 nM, 36 nM and 19 nM for HDAC4, HDAC5, HDAC7 and HDAC9 respectively. It has very weak or no activity targeting the other HDACs (2-40 μM). TMP269 has an unprecedented metal-binding group, trifluoromethyloxadiazole (TFMO), which circumvents the selectivity and pharmacologic liabilities of hydroxamates. Crystallography revealed a direct metal binding of the TFMO, and the chemo-proteomics approach demonstrated the superior selectivity of TMP269 relative to the other hydroxamate-substituted analogs via a chelating zinc-binding group. TMP269 alters gene expression unlike class I and IIb HDAC inhibitors and affects colony-stimulating factor responses. The discovery of TMP269 provides an alternative design for targeting metalloenzymes than the conventional chelating metal-binding group, and suggests a therapeutic potential for class IIa HDAC inhibitors that are distinct in mechanism and application compared to current HDAC inhibitors.